We have started this year strong by launching SOLIScript® SARS-CoV-2 RT-qPCR Multiplex Assay Kit on the market. So far it has been confirmed to detect Omicron (B.1.1.529) with 100% detection rate.
Since the start of the pandemic we have put a lot of care into developing the most efficient tools, so that everybody could accelerate their RT-qPCR testing to combat all the COVID-19 variants. When Omicron was designated as a variant of concern by WHO on the 26th of November it was quickly confirmed that Solis BioDyne’s very own IVD grade reagent SOLIScript® 1-step CoV Kit will not be tricked by the various mutations.
Now with the new SOLIScript® SARS-CoV-2 RT-qPCR Multiplex Assay Kit, which is currently for Research Use Only, it is possible to take testing even further. This product is based on SOLIScript® 1-step CoV Kit, but in addition supplied with all the primers, probes and positive control needed for SARS-CoV-2 detection. There is also proof from our partner diagnostic laboratory that it can detect Omicron (B.1.1.529) from clinical samples with 100% detection rate. Furthermore, the kit is 100% in agreement with LDT and Seegene CE-IVD kit.
Contact the experts at sales@solisbiodyne.com.
Read more about our products to improve your SARS-CoV-2 testing:
Meet our next-generation FIREScript® reverse transcriptases: fast, thermostable enzymes with distinct RNase H profiles for flexible cDNA synthesis and RT-qPCR workflows.
Summer has a way of changing the rhythm of a laboratory. Temperatures rise, team members take well-earned holidays, and deliveries do not always arrive exactly when expected. A shipment may take longer in transit than planned. A package might reach the laboratory on a particularly hot afternoon. With Solis BioDyne’s products, summer heat does not have to bring research to a standstill.
From 2010, Solis BioDyne had stepped into a whole new area of enzyme development. What began as an ambitious R&D project led to FIREScript®, SOLIScript®, RiboGrip® RNase Inhibitor, and the SolisFAST® product line. Find out more about the development process in this blog post.
In high-throughput environments such as diagnostic kit development, pharmaceutical research, and OEM manufacturing, reducing PCR and qPCR costs is rarely as simple as choosing the lowest-priced reagent. Cost per reaction is often the first metric considered, but it does not fully reflect the true financial impact of a workflow.
